Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its supply have become key concerns for patients and healthcare professionals. While tirzepatide has been cleared by regulatory agencies, its expensive nature presents a significant obstacle to ma